NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

研究用病毒載體製造的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各媒介型 (腺病毒、AAV、慢病毒)、工作流程、用途、終端用戶、地區

Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 1007473
出版日期 內容資訊 英文 250 Pages
商品交期: 2-10個工作天內
價格
研究用病毒載體製造的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各媒介型 (腺病毒、AAV、慢病毒)、工作流程、用途、終端用戶、地區 Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年05月10日內容資訊: 英文 250 Pages
簡介

全球研究用病毒載體製造的市場規模在預測期間內預計以18.8%的年複合成長率發展,2028年成長到39億美元的規模。

由於先進治療方法的研究基礎擴大,主要臨床前試驗,臨床試驗,臨床實驗等研究用途的市場擴大。新型冠狀病毒感染疾病 (COVID-19)的流行,尤其是帶給進入疫苗製造領域的經營者有利的機會。對SARS-CoV-2的疫苗開發的病毒載體的應用2020年顯示顯著的成長。

本報告提供全球研究用病毒載體製造的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19)以及其他的市場影響因素分析,市場規模的變化、預測,媒介型、工作流程、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 調查手法、調查範圍

第2章 摘要整理

第3章 市場可變因素、趨勢、展望

  • 市場分類、範圍
  • 市場動態
  • 普及、成長預測製圖
  • 波特分析
  • SWOT分析
  • 生產能力、服務的製圖
  • COVID-19:影響分析

第4章 市場預測、趨勢分析:各媒介型

  • 腺病毒
  • 反轉錄病毒
  • 腺結合病毒 (AAV)
  • 慢病毒
  • 其他

第5章 市場預測、趨勢分析:各工作流程

  • 上游處理
  • 下游處理

第6章 市場預測、趨勢分析:各用途

  • 遺傳基因、細胞治療的開發
  • 疫苗開發
  • 生物醫藥品、醫藥品的發現
  • 生物醫療研究

第7章 市場預測、趨勢分析:各終端用戶

  • 製藥、生物醫藥品企業
  • 研究機關

第8章 市場預測、趨勢分析:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭分析

  • 主要企業、近幾年的發展、影響分析
  • 企業、競爭上的分類
  • 廠商形勢
  • 業者情勢
  • 組合的企業的清單
  • 主要舉措、策略性聯盟
  • 公開企業
  • 非公開企業
  • 企業簡介:CMO
    • Merck kgaa
    • Lonza
    • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • Cobra Biologics Ltd.
    • Thermofisher Scientific Inc.
    • Waisman Biomanufacturing
    • genezen laboratories
    • YPOSKESI
    • Advanced BioScience Laboratories, Inc. (ABL inc.)
    • Novasep Holding s.a.s.
    • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
    • Vigene biosciences Inc.
    • General electric company (ge healthcare).
    • CEVEC. pharmaceuticals gmbh
    • Batavia Biosciences B.v.
    • Biovion oy
    • Wuxi AppTec Co., Ltd.
    • VGXI, Inc.
    • Catalent Inc.
    • Miltenyi Biotec gmbh
    • sirion biotech gmbh.
    • virovek incorporation
    • BioNTech IMFS GmbH
    • VIVEbiotech s.l.
    • creative biogene
    • Vibalogics GmbH
    • Takara Bio Inc.
  • 企業簡介:自家公司用製造
    • Cell and Gene Therapy Catapult
    • Bluebird Bio Inc.
    • Addgene Inc.
    • Aldevron LLc.
    • Astellas Pharma, Inc.
    • BioMarin Pharmaceutical, Inc.
    • RegenxBio, Inc.
目錄
Product Code: GVR-4-68039-359-7

Viral Vector Production (Research-use) Market Growth & Trends

The global viral vector production (research-use) market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.

The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.

Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.

Currently, several new gene therapy products are in the late stages of development and the pipeline continues to expand across the globe. The forward momentum for the advanced therapy arena is anticipated to drive investment to conduct research for the development of safe viral vectors and therapies.

Viral Vector Production (Research-use) Market Report Highlights

Adeno-associated virus (AAV) accounted for the largest revenue share in 2020. Proven records of non-pathogenicity are one of the important key factors boosting the adoption of this segment

Recently, usage of AAV is rising considerably across several therapeutic areas, consequently witnessing a significant boost in adoption rate throughout the forecast period

In terms of revenue share, the downstream processing segment dominated the market in 2020 owing to highly complex polishing and purification procedures of final products

Furthermore, the growing demand for viral vectors due to their increased adoption as therapeutics has led to an increase in the need for optimizing downstream and upstream workflows

This is driving investment flow in both segments, resulting in a significant share of upstream processing

Given the extensive efforts in COVID-19 vaccine development, the application of viral vectors in the vaccine development segment has witnessed tremendous growth, resulting in the largest revenue share of this segment in 2020

The research institutes segment dominated the market in terms of revenue share in 2020. The increasing involvement of scientific communities in gene and cell therapy research has driven the revenue flow in this segment

North America captured the maximum revenue share in 2020 with the U.S. at the forefront

One major factor that has contributed to the larger share of this regional market is the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies

Investments made by the federal bodies for the expansion of cell therapy research base in the region are anticipated to enhance the growth of the market in North America

The key market players are engaged in collaboration with pharma companies to serve their viral-vector-based research needs pertaining to advanced therapy development

Table of Content

Chapter 1 Executive Summary

  • 1.1 Viral Production Market (for Research Use Only) Outlook
    • 1.1.1 Market Summary

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Model
    • 2.3.1 Market Analysis, by Vector Type
      • 2.3.1.1 By characteristics/advantage & disadvantage
      • 2.3.1.2 By clinical trials
      • 2.3.1.3 By manufacturing service penetration/availability
    • 2.3.2 Market Study, By End Use
    • 2.3.3 Regional Analysis

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines
      • 3.2.1.2 Technological advancemnets in manufacturing vectors
      • 3.2.1.3 Highly competitive market and various strategies undertaken by market entities
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
    • 3.2.3 Market Challenge Analysis
      • 3.2.3.1 Production capacity challenges
      • 3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors
    • 3.2.4 Market Opportunity Analysis
      • 3.2.4.1 Facility expansion for cell and gene therapies
  • 3.3 Penetration & Growth Prospect Mapping for Vector Type, 2020
  • 3.4 Industry Analysis - Porter's
  • 3.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 3.6 Viral Vector Production Capacity & Service Mapping Analysis
    • 3.6.1 North America: Capacity & service mapping
    • 3.6.2 Europe: Capacity & Service Mapping
      • 3.6.2.1 Cobra Biologics (Sweden and the U.K.)
      • 3.6.2.2 Biovian (Finland)
      • 3.6.2.3 Oxford Biomedica (U.K.)
      • 3.6.2.4 Lonza Pharma & Biotech (The Netherlands)
      • 3.6.2.5 FinVector Oy (Finland)
      • 3.6.2.6 Fujifilm Diosynth Biotechnologies (Denmark)
      • 3.6.2.7 Fujifilm Diosynth Biotechnologies (U.K.)
      • 3.6.2.8 Catalent Inc. (Belgium)
      • 3.6.2.9 Novasep (Belgium)
      • 3.6.2.10 Exothera (Belgium)
      • 3.6.2.11 Delphi Genetics SA (Belgium)
      • 3.6.2.12 Yposkesi (France)
      • 3.6.2.13 VIVEbiotech (Spain)
      • 3.6.2.14 MolMed SpA (Italy)
      • 3.6.2.15 Anemocyte (Italy)
  • 3.7 COVID-19 Impact Analysis

Chapter 4 Vector Type Business Analysis

  • 4.1 Viral Vector Production (Research-use) Market: Vector Type Movement Analysis
  • 4.2 Adenovirus
    • 4.2.1 Adenovirus Viral Vector Production (Research-use) Market Estimates and Forecast for Adenovirus, 2017 - 2028 (USD Million)
  • 4.3 Retrovirus
    • 4.3.1 Retrovirus Viral Vector Production (Research-use) Market Estimates and Forecast for Retrovirus 2017 - 2028 (USD Million)
  • 4.4 Adeno-Associated Virus (AAV)
    • 4.4.1 Adeno-Associated Virus (AAV)Viral Vector Production (Research-use) Market Estimates and Forecast for AAV, 2017 - 2028 (USD Million)
  • 4.5 Lentivirus
    • 4.5.1 Lentivirus Viral Vector Production (Research-use) Market Estimates and Forecast for lentivirus, 2017 - 2028 (USD Million)
  • 4.6 Others
    • 4.6.1 Other Viral Vector Production (Research-use) Market Estimates and Forecast for others, 2017 - 2028 (USD Million)

Chapter 5 Workflow Business Analysis

  • 5.1 Viral Vector Production (Research-use) Market: Workflow Movement Analysis
  • 5.2 Upstream Processing
    • 5.2.1 Global Upstream Processing Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 5.2.2 Vector amplification and expansion
      • 5.2.2.1 Global vector amplification and expansion market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.2.3 Vector recovery/harvesting
      • 5.2.3.1 Global vector recovery/harvesting market estimates and forecast, 2017 - 2028 (USD Million)
  • 5.3 Downstream Processing
    • 5.3.1 Global Downstream Processing Market Estimates And Forecast for 2017 - 2028 (USD Million)
    • 5.3.2 Purification
      • 5.3.2.1 Global purification market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.3 Fill finish
      • 5.3.3.1 Global fill finish market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 6 Application Business Analysis

  • 6.1 Viral Vector Production (Research-use) Market: Application Movement Analysis
  • 6.2 Gene and Cell Therapy Development
    • 6.2.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Gene and Cell Therapy Development, 2017 - 2028 (USD Million)
  • 6.3 Vaccine Development
    • 6.3.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Vaccine development 2017 - 2028 (USD Million)
  • 6.4 Biopharmaceutical and Pharmaceutical Discovery
    • 6.4.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Biopharmaceutical And Pharmaceutical Discovery, 2017 - 2028 (USD Million)
  • 6.5 Biomedical Research
    • 6.5.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Biomedical Research, 2017 - 2028 (USD Million)

Chapter 7 End-Use Business Analysis

  • 7.1 Viral Vector Production (Research-use) Market: End-use Movement Analysis
  • 7.2 Pharmaceutical and Biopharmaceutical Companies
    • 7.2.1 Global Viral Vector Production (Research-use) Market Estimates and Forecast for Pharmaceutical And Biopharmaceutical Companies, 2017 - 2028 (USD Million)
  • 7.3 Research Institutes
    • 7.3.1 Global Viral Vector Production (Research-use) Market Estimates And Forecast for Research institutes, 2017 - 2028 (USD Million)

Chapter 8 Regional Business Analysis

  • 8.1 Viral Vector Production (Research-use) Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.2.2.2 U.S. viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.2.2.3 U.S. viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.2.2.4 U.S. viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Canada viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.2.3.2 Canada viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.2.3.3 Canada viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.2.3.4 Canada viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Germany viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.3.2.2 Germany viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.3.2.3 Germany viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.3.2.4 Germany viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 U.K. viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.3.3.2 U.K. viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.3.3.3 U.K. viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.3.3.4 U.K. viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 France viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.3.4.2 France viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.3.4.3 France viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.3.4.4 France viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.3.5 Spain
      • 8.3.5.1 Spain viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.3.5.2 Spain viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.3.5.3 Spain viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.3.5.4 Spain viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.3.6 Italy
      • 8.3.6.1 Italy viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.3.6.2 Italy viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.3.6.3 Italy viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.3.6.4 Italy viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 8.4.2 China
      • 8.4.2.1 China viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.4.2.2 China viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.4.2.3 China viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.4.2.4 China viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.4.3 Japan
      • 8.4.3.1 Japan viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.4.3.2 Japan viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.4.3.3 Japan viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.4.3.4 Japan viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 India viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.4.4.2 India viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.4.4.3 India viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.4.4.4 India viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.4.5 South Korea
      • 8.4.5.1 South Korea viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.4.5.2 South Korea viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.4.5.3 South Korea viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.4.5.4 South Korea viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.4.6 Australia
      • 8.4.6.1 Australia viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.4.6.2 Australia viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.4.6.3 Australia viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.4.6.4 Australia viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.5.2.2 Brazil viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.5.2.3 Brazil viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.5.2.4 Brazil viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Mexico viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.5.3.2 Mexico viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.5.3.3 Mexico viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.5.3.4 Mexico viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 8.6 MEA
    • 8.6.1 MEA Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.6.2.2 South Africa viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.6.2.3 South Africa viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.6.2.4 South Africa viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Saudi Arabia viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
      • 8.6.3.2 Saudi Arabia viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
      • 8.6.3.3 Saudi Arabia viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 8.6.3.4 Saudi Arabia viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)

Chapter 9 Competitive Analysis

  • 9.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 9.2 Company/Competition Categorization
  • 9.3 Manufacturer's Landscape
    • 9.3.1 Distribution by Location of Manufacturing Facility
    • 9.3.2 CDMOs Operating in China
    • 9.3.3 Distribution by Scale of Production
    • 9.3.4 Distribution by Location Of Manufacturing Facility, Type Of Organization, And Purpose Of Production
  • 9.4 Vendor Landscape
    • 9.4.1 List of Key Technology Supplier
    • 9.4.2 List of Raw Material/Technology Distributors
      • 9.4.2.1 Region-wise Bioprocessing Technology Distributors:
  • 9.5 List of Companies with Portfolio Comprising Viral Vector-based Therapeutic Candidates.
  • 9.6 List of Companies with Service Portfolio offering Viral Vector Manufacturing Services.
  • 9.7 Key Initiatives & Strategic Alliances Analysis
    • 9.7.1 Merger & Acquisition Deals
    • 9.7.2 Collaborations & Partnerships
    • 9.7.3 Business Expansion
    • 9.7.4 Technology Collaborations
  • 9.8 Public Companies Analysis
    • 9.8.1 Industry Players
      • 9.8.1.1 Takara Bio Inc.
      • 9.8.1.2 Fujifilm Diosynth Biotechnologies
      • 9.8.1.3 Batavia Biosciences B.V.
    • 9.8.2 Non-Industry Players
    • 9.8.3 Synergy Analysis: Major Deals & Strategic Alliances
  • 9.9 Private Companies
    • 9.9.1 List of key emerging companies
    • 9.9.2 Market Participation Categorization (Market Operations & Weakness)
    • 9.9.3 Strategy Framework
  • 9.10 Company Profiles: Contract Manufacturing Organizations (CMOs)
    • 9.10.1 Merck kgaa
      • 9.10.1.1 Company overview
      • 9.10.1.2 Sigma-aldrich Inc.
      • 9.10.1.3 Financial Performance
      • 9.10.1.4 Product benchmarking
      • 9.10.1.5 SWOT Analysis
      • 9.10.1.6 Operational Capacity
      • 9.10.1.7 strategic initiatives
    • 9.10.2 Lonza
      • 9.10.2.1 Company overview
      • 9.10.2.2 Financial Performance
      • 9.10.2.3 Product benchmarking
      • 9.10.2.4 SWOT Analysis
      • 9.10.2.5 Operational Capacity
      • 9.10.2.6 Srategic initiatives
    • 9.10.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
      • 9.10.3.1 Company overview
      • 9.10.3.2 Financial Performance
      • 9.10.3.3 Product benchmarking
      • 9.10.3.4 SWOT Analysis
      • 9.10.3.5 Operational Capacity
      • 9.10.3.6 Startegic initiatives
    • 9.10.4 Cobra Biologics Ltd.
      • 9.10.4.1 Company overview
      • 9.10.4.2 Product benchmarking
      • 9.10.4.3 SWOT Analysis
      • 9.10.4.4 Operational capacity
      • 9.10.4.5 strategic initiatives
    • 9.10.5 Thermofisher Scientific Inc.
      • 9.10.5.1 Company overview
      • 9.10.5.2 Financial Performance
      • 9.10.5.3 Product benchmarking
      • 9.10.5.4 SWOT analysis
      • 9.10.5.5 Operational capacity
      • 9.10.5.6 Startegic initiatives
    • 9.10.6 Waisman Biomanufacturing
      • 9.10.6.1 Company overview
      • 9.10.6.2 Product benchmarking
      • 9.10.6.3 Swot analysis
      • 9.10.6.4 Operational capacity
      • 9.10.6.5 Strategic inititaives
    • 9.10.7 genezen laboratories
      • 9.10.7.1 Company overview
      • 9.10.7.2 Product benchmarking
      • 9.10.7.3 SWOT Analysis
      • 9.10.7.4 Operational capacity
    • 9.10.8 YPOSKESI
      • 9.10.8.1 Company overview
      • 9.10.8.2 Product benchmarking
      • 9.10.8.3 SWOT Analysis
      • 9.10.8.4 Operational capacity
      • 9.10.8.5 Strategic initiaves
    • 9.10.9 Advanced BioScience Laboratories, Inc. (ABL inc.)
      • 9.10.9.1 Company overview
      • 9.10.9.2 Financial Performance
      • 9.10.9.3 Product benchmarking
      • 9.10.9.4 SWOT Analysis
      • 9.10.9.5 Operational capacity
      • 9.10.9.6 Strategic initiatives
    • 9.10.10 Novasep Holding s.a.s.
      • 9.10.10.1 Company overview
      • 9.10.10.2 Product benchmarking
      • 9.10.10.3 SWOT Analysis
      • 9.10.10.4 Operational Capacity
      • 9.10.10.5 Strategic initiatives
    • 9.10.11 Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
      • 9.10.11.1 Company overview
      • 9.10.11.2 Financial Performance
      • 9.10.11.3 Product benchmarking
      • 9.10.11.4 SWOT Analysis
      • 9.10.11.5 Operational Capacity
      • 9.10.11.6 Strategic initiatives
    • 9.10.12 Vigene biosciences Inc.
      • 9.10.12.1 Company overview
      • 9.10.12.2 Product benchmarking
      • 9.10.12.3 SWOT Analysis
      • 9.10.12.4 Operational capacity
      • 9.10.12.5 Startegic initiatives
    • 9.10.13 General electric company (ge healthcare).
      • 9.10.13.1 Company overview
      • 9.10.13.2 Financial Performance
      • 9.10.13.3 Product benchmarking
      • 9.10.13.4 SWOT Analysis
      • 9.10.13.5 Operational capacity
      • 9.10.13.6 Strategic initiatives
    • 9.10.14 CEVEC. pharmaceuticals gmbh
      • 9.10.14.1 Company overview
      • 9.10.14.2 Product benchmarking
      • 9.10.14.3 SWOT Analysis
      • 9.10.14.4 Operational capacity
      • 9.10.14.5 Strategic initiatives
    • 9.10.15 Batavia Biosciences B.v.
      • 9.10.15.1 Company overview
      • 9.10.15.2 Product benchmarking
      • 9.10.15.3 SWOT Analysis
      • 9.10.15.4 Operational capacity
      • 9.10.15.5 Strategic initiatives
    • 9.10.16 Biovion oy
      • 9.10.16.1 Company overview
      • 9.10.16.2 Product benchmarking
      • 9.10.16.3 SWOT Analysis
      • 9.10.16.4 Operational capacity
      • 9.10.16.5 Strategic initiatives
    • 9.10.17 Wuxi AppTec Co., Ltd.
      • 9.10.17.1 Company overview
      • 9.10.17.2 Financial Performance
      • 9.10.17.3 Product benchmarking
      • 9.10.17.4 SWOT Analysis
      • 9.10.17.5 Operational capacity
      • 9.10.17.6 Strategic initiatives
    • 9.10.18 VGXI, Inc.
      • 9.10.18.1 Company overview
      • 9.10.18.2 Product benchmarking
      • 9.10.18.3 SWOT Analysis
      • 9.10.18.4 Operational capacity
      • 9.10.18.5 Strategic initiatives5
    • 9.10.19 Catalent Inc.
      • 9.10.19.1 Company overview
      • 9.10.19.2 Paragon Bioservices Inc.
      • 9.10.19.3 Financial performance
      • 9.10.19.4 Product benchmarking
      • 9.10.19.5 SWOT Analysis
      • 9.10.19.6 Operational capacity
      • 9.10.19.7 Strategic initiatives
    • 9.10.20 Miltenyi Biotec gmbh
      • 9.10.20.1 Company overview
      • 9.10.20.2 Lentigen technology Inc.
      • 9.10.20.3 Product benchmarking
      • 9.10.20.4 SWOT Analysis
      • 9.10.20.5 Operational capacity
      • 9.10.20.6 Strategic initiatives
    • 9.10.21 sirion biotech gmbh.
      • 9.10.21.1 Company overview
      • 9.10.21.2 Product benchmarking
      • 9.10.21.3 SWOT Analysis
      • 9.10.21.4 Operational capacity
      • 9.10.21.5 Strategic initiatives
    • 9.10.22 virovek incorporation
      • 9.10.22.1 Company overview
      • 9.10.22.2 Product benchmarking
      • 9.10.22.3 SWOT Analysis
      • 9.10.22.4 Operational capacity
      • 9.10.22.5 Strategic initiaitves
    • 9.10.23 BioNTech IMFS GmbH
      • 9.10.23.1 Company overview
      • 9.10.23.2 Product benchmarking
      • 9.10.23.3 SWOT Analysis
      • 9.10.23.4 Operational capacity
    • 9.10.24 VIVEbiotech s.l.
      • 9.10.24.1 Company overview
      • 9.10.24.2 Financial Performance
      • 9.10.24.3 Product benchmarking
      • 9.10.24.4 SWOT Analysis
      • 9.10.24.5 Operational capacity
      • 9.10.24.6 Strategic initiatives
    • 9.10.25 creative biogene
      • 9.10.25.1 Company overview
      • 9.10.25.2 Product benchmarking
      • 9.10.25.3 SWOT Analysis
    • 9.10.26 Vibalogics GmbH
      • 9.10.26.1 Company overview
      • 9.10.26.2 Product benchmarking
      • 9.10.26.3 SWOT Analysis
      • 9.10.26.4 Operational capacity
      • 9.10.26.5 Strategic initiatives
    • 9.10.27 Takara Bio Inc.
      • 9.10.27.1 Company overview
      • 9.10.27.2 Financial Performance
      • 9.10.27.3 Product benchmarking
      • 9.10.27.4 SWOT Analysis
      • 9.10.27.5 Operational capacity
      • 9.10.27.6 Strategic initiaitves
  • 9.11 Company Profiles: In-house Manufacturers
    • 9.11.1 Cell and Gene Therapy Catapult
      • 9.11.1.1 Company overview
      • 9.11.1.2 Product benchmarking
      • 9.11.1.3 SWOT Analysis
      • 9.11.1.4 Operational capacity
      • 9.11.1.5 Strategic initiatives
    • 9.11.2 Bluebird Bio Inc.
      • 9.11.2.1 Company overview
      • 9.11.2.2 Financial Performance
      • 9.11.2.3 Product benchmarking
      • 9.11.2.4 SWOT Analysis
      • 9.11.2.5 Operational capacity
      • 9.11.2.6 Strategic initiatives
    • 9.11.3 Addgene Inc.
      • 9.11.3.1 Company overview
      • 9.11.3.2 Product benchmarking
      • 9.11.3.3 SWOT Analysis
      • 9.11.3.4 Operational capacity
      • 9.11.3.5 Strategic initiatives
    • 9.11.4 Aldevron LLc.
      • 9.11.4.1 Company overview
      • 9.11.4.2 Product benchmarking
      • 9.11.4.3 SWOT Analysis
      • 9.11.4.4 Operational capacity
      • 9.11.4.5 Strategic initiatives
    • 9.11.5 Astellas Pharma, Inc.
      • 9.11.5.1 Company overview
      • 9.11.5.2 Audentes Therapeutics
      • 9.11.5.3 Financial performance (Astellas Pharma Inc.)
      • 9.11.5.4 Product benchmarking
      • 9.11.5.5 SWOT Analysis
      • 9.11.5.6 Operational capacity
      • 9.11.5.7 Strategic initiatives
    • 9.11.6 BioMarin Pharmaceutical, Inc.
      • 9.11.6.1 Company overview
      • 9.11.6.2 Financial Performance
      • 9.11.6.3 Product benchmarking
      • 9.11.6.4 SWOT Analysis
      • 9.11.6.5 Operational capacity
      • 9.11.6.6 Strategic initiatives
    • 9.11.7 RegenxBio, Inc.
      • 9.11.7.1 Company overview
      • 9.11.7.2 Financial Performance
      • 9.11.7.3 Product benchmarking
      • 9.11.7.4 SWOT Analysis
      • 9.11.7.5 Operational capacity
      • 9.11.7.6 SWOT Analysis

List of Tables

  • Table 1 Viral vector characteristic analysis
  • Table 2 Viral vector-based COVID-19 vaccine candidates
  • Table 3 Operating CMOs/CDMOs for advanced therapy manufacturing in EU
  • Table 4 Most-used 2D devices used for LV production
  • Table 5 Fixed-bed bioreactors optimized for high-scale LV production
  • Table 6 Human clinical trials in progress with viral vectored vaccines
  • Table 7 List of key technology supplier for downstream processing
  • Table 8 List of key technology supplier for upstream processing
  • Table 9 Distributors list for Sartorius for key countries
  • Table 10 Distributors list for Cytiva for key countries
  • Table 11 List of key emerging companies
  • Table 12 Contract Manufacturing Organizations (CMOs) offering viral & non-viral vector manufacturing services
  • Table 13 Biozilla, LLC's plasmid purification cost
  • Table 14 AAV production: Pricing analysis
  • Table 15 AAV packaging, cloning, & titration: Pricing analysis
  • Table 16 Lentivirus production: Pricing analysis
  • Table 17 Lentivirus packaging, titration, & others: Pricing analysis
  • Table 18 Adenovirus production: Pricing analysis
  • Table 19 Adenovirus packaging, titration, & others: Pricing analysis
  • Table 20 Retrovirus production: Pricing analysis
  • Table 21 Plasmid production: Pricing analysis
  • Table 22 Plasmid DNA purification: Pricing analysis
  • Table 23 Eurofins Genomics LLC's gene synthesis cost analysis
  • Table 24 GenScript's gene synthesis cost analysis (GenPlus Economy Gene Synthesis)
  • Table 25 Eurofins Genomics LLC's gene fragments cost analysis
  • Table 26 North America viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 27 North America viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 28 North America viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 29 North America viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 30 North America viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 31 North America viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 32 U.S. viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 33 U.S. viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 34 U.S. viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 35 U.S. viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 36 U.S. viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 37 U.S. viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 38 Canada viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 39 Canada viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 40 Canada viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 41 Canada viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 42 Canada viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 43 Canada viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 44 Europe viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 45 Europe viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 46 Europe viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 47 Europe viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 48 Europe viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 49 Europe viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 50 Germany viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 51 Germany viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 52 Germany viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 53 Germany viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 54 Germany viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 55 Germany viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 56 U.K. viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 57 U.K. viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 58 U.K. viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 59 U.K. viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 60 U.K. viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 61 U.K. viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 62 France viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 63 France viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 64 France viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 65 France viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 66 France viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 67 France viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 68 Spain viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 69 Spain viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 70 Spain viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 71 Spain viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 72 Spain viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 73 Spain viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 74 Italy viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 75 Italy viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 76 Italy viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 77 Italy viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 78 Italy viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 79 Italy viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 80 Asia Pacific viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 81 Asia Pacific viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 82 Asia Pacific viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 83 Asia Pacific viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 84 Asia Pacific viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 85 Asia Pacific viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 86 China viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 87 China viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 88 China viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 89 China viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 90 China viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 91 China viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 92 Japan viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 93 Japan viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 94 Japan viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 95 Japan viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 96 Japan viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 97 Japan viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 98 India viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 99 India viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 100 India viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 101 India viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 102 India viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 103 India viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 104 South Korea viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 105 South Korea viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 106 South Korea viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 107 South Korea viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 108 South Korea viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 109 South Korea viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 110 Australia viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 111 Australia viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 112 Australia viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 113 Australia viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 114 Australia viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 115 Australia viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 116 Latin America viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 117 Latin America viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 118 Latin America viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 119 Latin America viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 120 Latin America viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 121 Latin America viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 122 Brazil viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 123 Brazil viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 124 Brazil viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 125 Brazil viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 126 Brazil viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 127 Brazil viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 128 Mexico viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 129 Mexico viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 130 Mexico viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 131 Mexico viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 132 Mexico viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 133 Mexico viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 134 MEA viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 135 MEA viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 136 MEA viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 137 MEA viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 138 MEA viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 139 MEA viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 140 South Africa viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 141 South Africa viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 142 South Africa viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 143 South Africa viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 144 South Africa viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 145 South Africa viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 146 Saudi Arabia viral vector production (research use) market estimates and forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 147 Saudi Arabia viral vector production (research use) market estimates and forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 148 Saudi Arabia viral vector production (research use) market estimates and forecasts, by upstream processing, 2017 - 2028 (USD Million)
  • Table 149 Saudi Arabia viral vector production (research use) market estimates and forecasts, by downstream processing, 2017 - 2028 (USD Million)
  • Table 150 Saudi Arabia viral vector production (research use) market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • Table 151 Saudi Arabia viral vector production (research use) market estimates and forecasts, by end use, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market snapshot, 2020 (USD Million)
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research process
  • Fig. 5 Primary research validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modeling
  • Fig. 9 Market formulation and validation
  • Fig. 10 Vector type characteristic analysis
  • Fig. 11 QFD model assessment for vector type
  • Fig. 12 Vector type characteristic analysis
  • Fig. 13 Lentiviral vectors versus AAV vectors
  • Fig. 14 Global number of AAV- and lentivirus-based clinical trials
  • Fig. 15 Gene therapy approvals versus clinical trials
  • Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
  • Fig. 17 Distribution of the sponsors of advanced therapies clinical trials, 2016
  • Fig. 18 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
  • Fig. 19 Gene therapy approvals versus clinical trials
  • Fig. 20 Penetration by end use settings
  • Fig. 21 Regional analysis for rare disease genetic testing market
  • Fig. 22 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
  • Fig. 23 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2019
  • Fig. 24 Market trends & outlook
  • Fig. 25 Market segmentation & scope
  • Fig. 26 Market driver relevance analysis (Current & future impact)
  • Fig. 27 Gene therapy clinical trials
  • Fig. 28 Viral vectors used in clinical trials
  • Fig. 29 Key strategies by market players to drive success in gene therapy arena
  • Fig. 30 Recent and upcoming approved gene transfer-mediated programs
  • Fig. 31 Market restraint relevance analysis (Current & future impact)
  • Fig. 32 Various ethical questions raised by gene therapy
  • Fig. 33 Major challenges in large-scale vector manufacturing
  • Fig. 34 Penetration & growth prospect mapping for vector type, 2020
  • Fig. 35 Porter's Five Forces Analysis
  • Fig. 36 SWOT analysis, by factor (Political & Legal, Economic and Technological)
  • Fig. 37 Viral vector production (research use) market : Vector type outlook and key takeaways
  • Fig. 38 Viral vector production (research use) market : Vector type movement analysis
  • Fig. 39 Viral vector production (research use) market estimates and forecast for Adenovirus 2017 - 2028 (USD Million)
  • Fig. 40 Viral vector production (research use) market estimates and forecast for retrovirus, 2017 - 2028 (USD Million)
  • Fig. 41 Viral vector production (research use) market estimates and forecast for AAV, 2017 - 2028 (USD Million)
  • Fig. 42 Viral vector production (research use) market estimates and forecast for Lentivirus, 2017 - 2028 (USD Million)
  • Fig. 43 Viral vector production (research use) market estimates and forecast for Others, 2017 - 2028 (USD Million)
  • Fig. 44 Viral vector production (research use) market : Workflow outlook and key takeaways
  • Fig. 45 Viral vector production (research use) market : Workflow movement analysis
  • Fig. 46 Global upstream processing market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 47 Global vector amplification and expansion market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 48 Global vector recovery/harvesting market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 49 Global downstream processing market estimates and forecast, for 2017 - 2028 (USD Million)
  • Fig. 50 Global purification market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 51 Global fill finish market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 52 Viral vector production (research use) market : Application outlook and key takeaways
  • Fig. 53 Viral vector production (research use) market : Application movement analysis
  • Fig. 54 Percentage of viral vector in gene therapy clinical trials as of April 2019
  • Fig. 55 Viral vector production (research use) market estimates and forecast for gene and cell therapy development, 2017 - 2028 (USD Million)
  • Fig. 56 Viral vector manufacturing market(research use) estimates and forecast for vaccine development, 2017 - 2028 (USD Million)
  • Fig. 57 Viral vector production (research use) market estimates and forecast for biopharmaceutical and pharmaceutical discovery, 2017 - 2028 (USD Million)
  • Fig. 58 Viral vector production (research use) market estimates and forecast for biomedical research, 2017 - 2028 (USD Million)
  • Fig. 59 Viral vector production (research use) market : End-use outlook and key takeaways
  • Fig. 60 Viral vector production (research use) market : End-use movement analysis
  • Fig. 61 Global viral vector production (research use) market estimates and forecast for pharmaceutical and biopharmaceutical companies 2017 - 2028 (USD Million)
  • Fig. 62 Global viral vector production (research use) market estimates and forecast, for research institutes 2017 - 2028
  • Fig. 63 Viral vector production (research use) market : Regional outlook and key takeaways
  • Fig. 64 Viral vector production (research use) market : Regional movement analysis
  • Fig. 65 North America viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 66 U.S. viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 67 Canada. viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 68 Europe viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 69 Germany viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 70 U.K. viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 71 France viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 72 Spain viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 73 Italy viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 74 Asia Pacific viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 75 China viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 76 Japan viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 77 India viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 78 South Korea viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 79 Australia viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 80 Latin America viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 81 Brazil viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 82 Mexico viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 83 MEA viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 84 South Africa viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 85 Saudi Arabia viral vector production (research use) market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 86 New developments-based initiatives by key market participants
  • Fig. 87 Impact analysis of new developments by key market participants
  • Fig. 88 Company/competition categorization
  • Fig. 89 Distribution by location of manufacturing facility
  • Fig. 90 CDMOs operating in China
  • Fig. 91 Distribution by scale of production
  • Fig. 92 Company mapping analysis, by manufacturing facility, type of organization, and purpose of production
  • Fig. 93 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
  • Fig. 94 Key public companies: Heat map analysis
  • Fig. 95 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
  • Fig. 96 Synergy analysis: Major deals & strategic alliances
  • Fig. 97 Participant categorization
  • Fig. 98 Strategy framework
  • Fig. 99 SWOT analysis Merck
  • Fig. 100 SWOT analysis Lonza
  • Fig. 101 SWOT analysis FUJIFILM
  • Fig. 102 SWOT analysis Cobra Biologics
  • Fig. 103 SWOT analysis Brammer Bio
  • Fig. 104 SWOT analysis Waisman Biomanufacturing
  • Fig. 105 SWOT analysis Genezen
  • Fig. 106 SWOT analysis YPOSKESI
  • Fig. 107 SWOT analysis ABL Inc.
  • Fig. 108 SWOT analysis Novasep Holding S.A.S
  • Fig. 109 SWOT analysis Orgenesis Biotech Israel Ltd
  • Fig. 110 SWOT analysis Vigene Biosciences
  • Fig. 111 SWOT analysis GE Healthcare
  • Fig. 112 SWOT analysis Cevec Pharmaceuticals GmbH
  • Fig. 113 SWOT analysis Batavia Biosciences
  • Fig. 114 SWOT analysis Biovion
  • Fig. 115 SWOT analysis Wuxi AppTec Co Ltd.
  • Fig. 116 SWOT analysis VGXI Inc.
  • Fig. 117 SWOT analysis Paragon Servicest Inc.
  • Fig. 118 SWOT analysis Lentigen Technology
  • Fig. 119 SWOT analysis Sirion Biotech GmbH
  • Fig. 120 SWOT analysis Virovek Incorporation
  • Fig. 121 SWOT analysis BioNTech
  • Fig. 122 SWOT analysis VIVEbiotech
  • Fig. 123 SWOT analysis Creative Biogene
  • Fig. 124 SWOT analysis Vibalogics GmbH
  • Fig. 125 SWOT analysis Takara BioInc.
  • Fig. 126 SWOT analysis cell and gene therapy catapult
  • Fig. 127 SWOT analysis Bluebird Bio Inc.
  • Fig. 128 SWOT analysis Addgene Inc.
  • Fig. 129 SWOT analysis Aldevron LLC
  • Fig. 130 SWOT analysis Audentis
  • Fig. 131 SWOT analysis BioMarin Pharmaceuticals
  • Fig. 132 SWOT analysis REGENXBIO Inc.